Literature DB >> 16189814

Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials.

Tze Leung Lai1, Mei-Chiung Shih, Guangrui Zhu.   

Abstract

In designing an active controlled clinical trial, one sometimes has to choose between a superiority objective (to demonstrate that a new treatment is more effective than an active control therapy) and a non-inferiority objective (to demonstrate that it is no worse than the active control within some pre-specified non-inferiority margin). It is often difficult to decide which study objective should be undertaken at the planning stage when one does not have actual data on the comparative advantage of the new treatment. By making use of recent advances in the theory of efficient group sequential tests, we show how this difficulty can be resolved by a flexible group sequential design that can adaptively choose between the superiority and non-inferiority objectives during interim analyses. While maintaining the type I error probability at a pre-specified level, the proposed test is shown to have power advantage and/or sample size saving over fixed sample size tests for either only superiority or non-inferiority, and over other group sequential designs in the literature. Copyright 2005 John Wiley & Sons, Ltd.

Mesh:

Year:  2006        PMID: 16189814     DOI: 10.1002/sim.2357

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial.

Authors:  Jonathan Mermin; John P Ekwaru; Willy Were; Richard Degerman; Rebecca Bunnell; Frank Kaharuza; Robert Downing; Alex Coutinho; Peter Solberg; Lorraine N Alexander; Jordan Tappero; James Campbell; David M Moore
Journal:  BMJ       Date:  2011-11-09

2.  A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).

Authors:  John J V McMurray; David L DeMets; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Anna M Langkilde; Felipe A Martinez; Olof Bengtsson; Piotr Ponikowski; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon
Journal:  Eur J Heart Fail       Date:  2019-03-21       Impact factor: 15.534

3.  Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol.

Authors:  Peter J Blankestijn; Kathrin I Fischer; Claudia Barth; Krister Cromm; Bernard Canaud; Andrew Davenport; Diederick E Grobbee; Jörgen Hegbrant; Kit C Roes; Matthias Rose; Giovanni Fm Strippoli; Robin Wm Vernooij; Mark Woodward; G Ardine de Wit; Michiel L Bots
Journal:  BMJ Open       Date:  2020-02-05       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.